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Abstract Azole antifungal compounds are important in the 
treatment of Cryptococcosis, a major cause of mortality in AIDS 
patients. The target of the azole drugs is P450 mediated sterol 
14a-demethylase. We have investigated the P450 system of Cryp- 
tococcus neoformans with respect o azole tolerance observed in 
clinical isolates which were obtained following the failure of flu- 
conazole therapy. The clinical failure was correlated with in vitro 
tolerance of azole antifungal when compared to wild-type strains. 
The microsomal P450 system was typical of yeast and fungi and 
fluconazole tolerance was not associated with defective sterol 
biosynthesis. The strains had slightly elevated P450 content and 
slightly reduced azole levels in the cells, but a clear cause for 
resistance was the increased level of drug needed to inhibit the 
sterol 14a-demethylase in vitro. 
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1. Introduction 
Cryptococcal disease is the most common life-threatening 
fungal infection associated with AIDS [1]. Cryptococcus neofor- 
roans may gain access through inhalation, but with immunode- 
ficiency disseminates widely, especially to the central nervous 
system causing meningitis. The main antifungal gents used to 
treat infection are amphotericin B, which has a mode of action 
involving binding to ergosterol [2], and azole antifungals, par- 
ticularly fluconazole, which inhibit P450-mediated sterol 14a- 
demethylase [3]. Failure of clinical azole antifungal therapy has 
been increasing [4] and we have examined sterol biosynthesis 
and the P450 systems of various wild-type strains and of strains 
associated with therapeutic failure. 
Resistance to azole antifungals has been relatively poorly 
understood at the molecular level except in Saccharomyces 
cerevisiae. Sterol 14a-demethylase is a member of the 
CYP51A1 family of P450s [5] and S. cerevisiae mutants defec- 
tive in this enzyme have been observed to be resistant to azole 
antifungals [6,7]. Azole resistance has been shown in mutants, 
selected irectly, to be caused by defects in sterol 35,6 desaturase 
[8] and such mutations are required as suppressors in strains 
containing blocked sterol 14a-demethylase [9].Complementa- 
tion studies have shown that in the strains containing both 
sterol 14a-demethylase nd sterol/I 5,6 desaturase that the latter 
defect is solely responsible for resistance [8]. The basis for the 
involvement ofsterol A 5'6 desaturase is it's role in the formation 
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of 14ct-methylergosta-8,24(28)-dien-3fl,6~-diol which d es not 
support growth. In sterol A 5'6 desaturase mutants the formation 
of this abnormal sterol is blocked and 14ct-methylfecosterol 
accumulates which supports growth. 
Studies on other pathogenic fungi have indicated a variety 
of changes which maybe associated with resistance including 
altered cellular content of azole, altered P450 content or altered 
P450 (for review see [10]). In some cases more than one pheno- 
typic change has been observed, even in parent and mutant 
comparison [11], but multiple mutation would appear unlikely 
as a common cause for clinical resistance on grounds of prob- 
ability. As the association of P450 lesion with sterol desaturase 
mutation has been observed in Candida albicans [10] similarity 
to the situation in S. cerevisiae may occur. One disturbing 
prospect isthe possibility of cross-resistance to azole antifungal 
and amphotericin B which could result from defective sterol A 5'6 
desaturation [8]. 
One potential difference between the mode of action of azole 
antifungals in C. neoformans and S. cerevisiae and other fungi 
accumulating the abnormal diol under treatment e.g.C, albi- 
cans, C. glabrata and A. fumigatus [10] also stimulated our 
interest. This was the observation of ketosteroid at high levels 
rather than the diol [12] suggesting alternative mechanisms of
resistance may arise as the formation of ketosteroids uring C4 
demethylation proceeds the formation of substrate for A 5'6 de- 
saturation. We describe here our studies on characterisation f 
azole antifungal tolerance in C. neoformans from AIDS patients 
who failed azole antifungal therapy. 
2. Materials and methods 
2.1. Strains 
Three azole sensitive strains were used; B4500 (Serotype D, 24), AI 8 
(Serotype A, from AIDS patient) and N7 (Serotype A, from non-AIDS 
patient). Four clinical isolates (Serotype A) were used from AIDS 
patients who failed fluconazole therapy and subsequently succumbed 
to Cryptococcosis; R715, R716, R717 and R718. Strains were routinely 
cultured on YEPD medium comprising 2% (w/v) glucose, 2% (w/v) 
Difco peptone and 1% (w/v) Difco yeast extract. 
2.2. Chemicals 
All chemicals were purchased from Sigma Chemical Company unless 
otherwise stated. Ketoconazole and itraconazole were purchased from 
Janssen Pharmaceutica and fluconazole was a gift from Pfizer Central 
Research. 
2.3. Cell inhibition studies 
Stationary phase cells, obtained from plate cultures incubated at 
37°C for 3 days were resuspended at 5 x 103cells/ml in YEPD medium. 
Treatment with various doses of antifungal compound occurred over 
3 days in 2 ml of medium in a Sterilin 60 ml container. Incubation was 
at 37°C, 150rpm and growth assessed by cell counts and colony-form- 
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ing units/ml. Each test was repeated at least three times and minimum 
inhibitory concentrations were constant. 
2.4. Cellular content of fluconazole 
The cellular levels of fluconazole were investigated using [14C]flucon- 
azole (specific activity 22.2/2Ci/mg). 109 cells were incubated in tripli- 
cate with 2 x 10 -5 M [~4C]ftuconazole in 0.1 M potassium phosphate 
buffer pH7 at 37°C, 150 rpm. The cells were harvested by centrifuga- 
tion and washed three times in 10 ml 10 4 M unlabelled fluconazole 
prior to collection on Whatman GFC filters. This procedure was used 
to establish a favourable fluconazole concentration gradient to reduce 
loss of radiolabelled fluconazole from the cells and to wash off non- 
specifically bound fluconazole. Cellular azole content, a balance of 
uptake and efflux, was monitored with time and had reached a plateau 
by 30 min. Use of autoclaved cells indicated a background of nonspe- 
cific binding at less than 10% of the values shown. The samples were 
assayed for radioactivity on a Philips 4700 Scintillation Counter and 
efficiency was estimated using the external standard method. 
2.5. Cell-free extracts and microsomal fractions 
C. neoformans strains were grown in YEPD medium in 1 liter cultures 
at 37°C, 150 rpm in 2 liter flasks. Cells were harvested when growth 
was at 108 cells/ml and washed in sterile water. Cell homogenisation 
of batches of 20 g wet wt. of cells was carried out using a Braun 
disintegrator (Braun GmbH, Mesungen, Germany) operating at 4000 
rpm with 4 × 30 s bursts with liquid carbon dioxide cooling. 20 g of glass 
beads (0.45-0.5 mm) were mixed with the cells and made up to 50 ml 
using 20% glycerol, 100 mM phosphate buffer pH 7.4. Cell free extracts 
were obtained following centrifugation at 1500 × g and protein concen- 
tration determined using bicinchoninic acid method (Sigma). For micro- 
somal fractions the cell-free extract was subject o further centrifuga- 
tion, first at 10000 x g to pellet mitochondria nd subsequently at 
100000 × g to produce the microsomal pellet. This was resuspended to
approximately 10 mg protein/ml in 20% glycerol, 100 mM phosphate 
pH 7.4 and P450 estimated using the method of Omura and Sato [15]. 
the cell-free biosynthesis of ergosterol was assayed. The reaction mix- 
ture consisted of cell-free xtract (924/21/ml) and cofactor solution (50 
/21;containing 1/2mol NADP; 1/2mol NADPH; l/2mol NAD, 3/2mol 
glucose 6-phosphate, 5/2tool ATP and 3/2mol reduced glutathione in
distilled water). The complete mixture was adjusted to pH 7 (by addition 
of 10 M KOH), divalent cation solution (10/21 of 0,5 M MgC12 and 
5/21 of 0.4 M MnC12), solution of azole compound issolved in dimeth- 
ylsulphoxide (1/21) and [2-C~4]mevalonate (10/21; 0.25/2Ci, 4.7 nmol). 
The mixture was incubated ina water bath at 37°C for 2 h with shaking 
(110 rpm), after which the reaction was stopped by adding lml of a 
freshly prepared saponification reagent (15% (w/v) KOH in 90% (v/v) 
ethanol). Non-saponifiable lipids (sterols and sterol precursors) were 
then extracted with 2 × 3 ml heptane and dried under nitrogen. The 
non-saponifiable lipid was applied to silica gel thin layer chromatogra- 
phy (TLC) plates (ART 573, Merck) and developed using cyclohexane: 
diethyl ether 9:1 (v/v). Radioactive metabolites were located by autora- 
diography and excised for scintillation counting. The production of 
4-desmethyl sterol was assessed for inhibition as described previously 
[18] and comprised more than 30% of the sterol produced. Experiments 
were performed in triplicate and IC50 values for ergosterol biosynthesis 
calculated. 
2.7. Identification of sterols by GC/MS 
Samples for GC/MS were prepared from 100 ml cultures in the 
exponential phase of growth. The sample was saponified in 15% (w/v) 
KOH in 90% (v/v) ethanol at 80°C for lh. Non-saponifiable ipids 
(sterol and sterol precursors) were then extracted with 2 x 5 ml heptane 
and dried under nitrogen. For determination f sterol composition a 
Hewlett/Packard GC/MS was used containing an Ultra 1 capillary 
column (10 m × 0.2 id) on a temperature programme 50°C (1 min) 
increased by 40°C/min to 290°C with a total run time of 17 min. 
Injection port temperature was 280°C (splitless) and the carrier gas was 
helium at 40 kPa. 
3. Results 
2.6. Inhibition of 14a-demethylase activity 
Azole antifungal inhibition of P450 was investigated by assessing the 
cell-free biosynthesis of ergosterol, according to methods imilar to 
previous tudies [11,16,17]. After centrifugation at 1500 × g for 5 rain 
3.1. In vitro tolerance of  azoles 
The C. neoformans wild-type and clinical isolates were exam- 
ined for their azole MICs with the commonly used, orally 
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Fig. 1. Structural formulae of azole antifungal compounds used. 
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Fig. 2. (a) Carbon monoxide difference spectrum of reduced cytochrome P450 in microsomes prepared from the C. neoformans isolate R715. (b) Type 
II difference spectrum produced by the interaction of fluconazole with microsomes from the clinical isolate R717. 
administered azole antifungals; fluconazole, itraconazole and 
ketoconazole (Fig. 1), In common with other studies flucon- 
azole was the least potent inhibitor of growth of the three, but 
for all antifungals the clinical isolates R715, R716, R717 and 
R718 showed tolerance in comparison to N7, A18 or B4500. 
The MICs observed for the clinical isolates was approximately 
tenfold higher than for N7, A18 or B4500 (Table la). The 
biochemical basis of this tolerance was then investigated, but 
did not involve degradation of azole as indicated following 
incubation of [14C]fluconazole with the strains (data not pre- 
sented). 
Table la 
The minimum inhibitory concentration values of fluconazole, ketocon- 
azole and itraconazole to growth of C. neoformans strains 
Minimum inhibitory concentration (tiM) 
Strain Fluconazole Ketoconazole Intraconazole 
B4500 2.0 0.25 0.2 
N7 1.0 0.1 0.1 
A18 1.0 0.1 0.1 
R715 20.0 2.5 5.0 
R716 10.0 2.0 2.0 
R717 20.0 2.0 5.0 
R718 20.0 4.0 5.0 
3.2. Sterol composition of the strains 
Sterol analysis did not indicate any overall change in the 
azole-tolerant clinical isolates as might be conferred by strin- 
gent blocks or leaky mutations in enzymes of the ergosterol 
biosynthetic pathway (Table lb), All strains accumulated ap- 
proximately 70% ergosterol in accord with our previous analy- 
sis of wild-type C. neoformans [13]. 
3.3. Study of  C. neoformans microsomal P450 
Using mechanical breakage it was possible to produce micro- 
somal fractions of the different isolates which displayed re- 
duced carbon monoxide difference spectra with a Soret maxi- 
mum at 448nm (Fig. 2a). Problems associated with cytochrome 
oxidase contamination which obscure this peak were observed 
if breakage conditions were too harsh. All the microsomal 
fractions exhibited typical Type II spectra when azole antifun- 
gal was added indicating binding to the haem as a sixth ligand 
(Fig. 2b; [10]). The specific content of P450 in the fractions was 
observed to be higher in the azole tolerant isolates, approxi- 
mately twice the level of N7, A18 and B4500 (Table 2), The 
specific content observed in all the C. neoformans strains was 
comparable to the strains of S. cerevisiae which have the highest 
levels of microsomal P450 [14]. 
Table lb 
Sterol composition of C. neoformans strains 
Percentage sterol composition of wild type and azole-tolerant isolates 
B4500 A18 N7 R715 R716 R717 R718 
Ergosterol 70.0 64.0 79.5 71.5 75.6 76.6 71.4 
Ergosta-7,22-dienol 3.0 - - - 
Ergosta-5,7-dienol 2.0 - 
Ergosta-7-enol 13.5 4.2 11.0 16.4 14.4 13.0 17.4 
4-Methylergosta-8,24(28)-dienol 5.0 2.0 2.0 . . . . . .  
4,4-Dimethylergosta-8,24(28)-dienol 6.5 2.1 7.5 
24-Methylene-24,25-dihydrolanosterol 5.0 27.7 
Unknown 0.0 - 12.1 10.0 20.4 11.2 
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Table 2 
Relationship of microsomal P450 cellular content and cellular [~4C]flu- 
conazole levels for C neoformans strains expressed aslevels per cell 
Strain P450/Cell (pmol) Fluconazole/Cell (pmol) 
B4500 0.7 × 10 8 2.4 × 10 -7 
N7 0.7 × 10 -8 2.2 × 10 -7 
A18 0.6 × 10 -8 2.1 × 10 -v 
R715 1.4 x 10 -8 1.1 × 10 -7 
R716 1.6 x 10 -8 1.2 x 10 -7 
R717 1.5 × 10 -8 1.6 x 10 7 
R718 1.7× 10 -8 1.4× 10 7 
Table 3 
lCso values of fluconazole, ketoconazole and itraconazole on incorpo- 
ration of [2-t4C]mevalonate in o C4-desmethyl sterols in cell-free x- 
tracts of sensitive and tolerant C. neoformans strains 
ICs0 values for in vitro ergosterol biosynthesis (nM) ~ 
Strain Fluconazole Ketoconazole Itraconazole 
B4500 400 + 150 4.0 + 2.0 3.7 + 1.5 
N7 300 + 210 3.4 _+ 2.3 2.3 + 1.5 
AI8 600 + 200 3.0 + 1.7 4.1 + 2.0 
R715 5000 + 3000 27.0 + 12.0 27.0 _+ 21.0 
R716 3500 + 2000 33.0 +_ 21.0 31.0 + 18.0 
R717 3300 + 2000 53.0 + 11.0 43.0 + 21.0 
R718 5000 + 3200 57.0 + 20.0 47.0 + 12.0 
Values hown +_ standard eviation. 
3.4. Comparison of  azole content in cells 
Cellular content of azole antifungal in the strains was inves- 
tigated using [~4C]fluconazole. The time course of accumulation 
of fluconazole was investigated and observed to plateau after 
treatment for 30 min. The content of fluconazole was reduced 
in all the tolerant isolates in comparison to N7, A18 and B4500 
(Table 2). However, the content of intracellular zole was still 
in excess of the microsomal P450 content when related to the 
amounts of each per cell (Table 2). 
3.5. Investigation of inhibition of sterol 14a-demethylation 
Using cell-free xtracts of all the strains ICs0 determinations 
for inhibition of ergosterol biosynthesis were made for itracon- 
azole, ketoconazole and fluconazole. In all cases the ICs0 values 
correlated with the observed in vitro tolerance of the strains 
and showed approximately tenfold differences in sensitivity 
between the tolerant strains R715, R716, R717, R718 and the 
wild-type strains N7, A18 and B4500 (Table 3). 
4. Discussion 
The present studies have demonstrated for the first time an 
alteration of P450 to be related to azole tolerance. The molec- 
ular basis of azole resistance in fungi is a subject of current 
interest due to its emergence as a clinical problem and also in 
agriculture [10]. Sterol A 5,6 desaturase has been shown to play 
a critical role in azole mode of action and resistance in 
S. cerevisiae, being required for the formation of 14a-methyler- 
gosta-24(28)-dien-3fl,6a-diol under azole antifungal treatment, 
which is incompatible with sterol function in membranes [15]. 
Mutants blocked in this enzyme do not synthesise the diol and 
accumulate the precursor sterol, 14a-methylfecosterol, which 
is capable of supporting rowth. Previously, it has been shown 
that C. neoformans does not accumulate 14c~-methyl-3,6-diol or 
14~-methylfecosterol to a high level under azole treatment and 
thus other mechanisms of resistance must operate [12]. 
Ketosteroid accumulation, particularly for obtusifolione, to 
high levels and ergosterol reduction in azole-treated C. neofor- 
roans could be resisted by either azole degradation, a mutation 
altering sterol biosynthesis (apart from sterol 14ct-demethy- 
lase), elevation of the cellular content of the target enzyme, 
alteration of affinity of the target enzyme for the drug or the 
development of mechanisms for reducing cellular content of the 
drug. 
Tolerance was observed to be unrelated to azole degradation 
or to defective sterol biosynthesis in genes other than encoding 
sterol 14~-demethylase  was observed in S. cerevisiae. Our 
observation of ergosterol as the predominant s erol of all the 
strains tudied is in accord with a previous tudy [12,13]. Others 
have observed lower levels of ergosterol [I 8], but this may have 
been due to harvesting cells in stationary phase where we have 
observed a similar effect. The accumulation of obtusifolione 
following azole treatment in C. neoformans indicates interfer- 
ence with the process of C4 demethylation where the last step 
involves aketosteroid reductase [19]. Interference with this step 
may be due to a direct effect of azole, or more likely, inhibition 
caused by retention of the 14a-methyl group in the substrate 
as appears to occur for S. cerevisiae during attempted A 5"6 
desaturation [8]. Whatever the origin of the effect there appears 
to be a difference in sensitivity between the ketosteroid reduc- 
tases of different fungal species. Previous tudies have indicated 
that the 14c~-methyl sterols preceeding this step, including 
eburicol, will not support growth [20] and this was consistent 
with our observations that a block to sterol biosynthesis was 
not associated with azole tolerance. 
Gene dosage ffects can result in increased resistance toazole 
antifungals, but elevation of the enzyme by 100-fold in a 
S. cerevisiae heterologous expression systems only altered the 
MIC fivefold [10]. The observation of a raised specific content 
of P450 in microsomal fractions from R715, R716, R717 and 
R718 provides ome support for a similar role. However, the 
elevation would be unlikely to account for their resistance un- 
less a dramatic increase in sterol 14~-demethylase was masked 
by the presence of other major P450 enzymes in the microsomal 
fractions of the wild-type strains. In S. cerevisiae sterol 14a- 
demethylase is the major P450 of vegetatively growing yeast 
[21], but confirmation that this also the case in C neoJormans 
will require further purification studies. Antibodies raised 
against he S. cerevisiae sterol 14~-demethylase do not cross- 
react with microsomal fractions of C neoformans to allow any 
immediate immunological studies (unpublished observation). 
Studies on Candida albicans [22] and Penicillium itaficum [23] 
have observed reduced cellular levels of azole antifungal com- 
pounds associated with resistance. Such observations have led 
to the suggestion that alterations similar to those resulting in 
multiple-drug resistance are occurring [8]. Slightly reduced 
azole content per cell was observed for the azole tolerant 
strains, but no cross-resistance to other antifungal compounds 
like amphotericin B or cycloheximide (data not presented). 
Although this reduced accumulation of drug might be associ- 
ated with the azole-tolerant phenotype, we examined the basis 
of this hypothesis one stage further by relating the azole content 
of the cells to their microsomal P450 content. Even when azole 
content was reduced it was still an order of magnitude in excess 
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of the P450 suggesting ample drug was available for growth 
inhibition. Without developing further theories related to the 
compartmentalisation of azole antifungal within the cell we 
considered the basis of tolerance was probably not related to 
the changes in cellular content of azole antifungal. 
The in vitro inhibition of ergosterol biosynthesis provided an 
obvious cause of azole tolerance based on a change in concen- 
tration of azole required to inhibit sterol 14~-demethylation. 
R715, R716, R717 and R718 required approximately tenfold 
higher concentrations of azole in order to provide equivalent 
inhibition to N7, A18 and B4500 as was observed for variation 
in sensitivity in whole cells. This alteration may be due to 
changes in the level of the target P450 for azole antifungals, 
although alterations in the active site which retain catalytic 
activity, but have altered affinity for azole is perhaps more 
likely given the considerations above. Further studies are war- 
ranted to understand the molecular biology of the altered sterol 
14~-demethylation step as well as extension to determine the 
extent of clinical relevance. 
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